Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis.
NCT ID: NCT06032039
Last Updated: 2024-05-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
EARLY_PHASE1
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-01
Study Completion Date
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will explore the effectiveness of intra-articular knee injections in patients with osteoarthritis by comparing Corticosteroid (triamcinolone) vs Platelet Rich Plasma (PRP).
This study is a randomized controlled trial with a sample size of one hundred and sixty patients (160). Patients would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies) with knee osteoarthritis.
The aim of the study is to:
1. To determine if platelet-rich plasma injections are better at improving functional outcomes in the knee using Western Ontario and McMaster Universities Arthritis Index (WOMAC) when compared to intraarticular steroids.
2. To identify adverse reactions related to these injections
This study is a randomized controlled trial with a sample size of one hundred and sixty patients (160). Patients would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies) with knee osteoarthritis.
The aim of the study is to:
1. To determine if platelet-rich plasma injections are better at improving functional outcomes in the knee using Western Ontario and McMaster Universities Arthritis Index (WOMAC) when compared to intraarticular steroids.
2. To identify adverse reactions related to these injections
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraarticular Platelet-rich Plasma Injections Versus Corticosteroid Injections in Primary Knee Osteoarthritis
NCT01923909
Osteoarthritis
WITHDRAWN
PHASE4
Knee Injections for Obese Patients With Knee Arthritis
NCT06782529
Osteoarthritis of Knee
RECRUITING
PHASE4
Do Knee Injections Offer Benefit With Knee Arthritis Pain
NCT04017949
Knee Osteoarthritis
COMPLETED
Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.
NCT03086759
Knee Osteoarthritis
COMPLETED
PHASE4
Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain
NCT06703970
Knee Osteoarthritis (OA)
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will explore the effectiveness of intra-articular knee injections in patients with osteoarthritis by comparing Corticosteroid (triamcinolone) vs Platelet Rich Plasma (PRP).
This study is a randomized controlled trial with a sample size of one hundred and sixty patients (160). Patients would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies) with knee osteoarthritis.
The recruitment period will run from July 31, 2023 to January 31, 2024 and a subsequent year of follow-up for each patient.
Selected patients will be informed of the study and given informed consent to fill out once they meet the inclusion criteria. Information will be stored on a password-encrypted external storage device that can only be accessed by the investigator or supervisor. Data will be analyzed using Statistical Package for the Social Sciences (SPSS).
The study will be conducted according to the good clinical practice guidelines of the World Medical Association (WMA) declaration of Helsinki which addresses research on human subjects and will conform to local laws and ethical requirements of the Ministry of Health.
The study will provide information on the effectiveness of two non-operative management of osteoarthritis of the knee; in the form of Platelet-rich plasma and corticosteroid injection. Results from the study can be used as a reference point for future treatment in patients with knee osteoarthritis.
Hypothesis:
PRP is superior to corticosteroid intra-articular injection over one year for knee pain and functional outcome in patients with osteoarthritis of the knee
Design This study is a randomized controlled double-blinded trial. Patients with knee osteoarthritis would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies).
The intervention will be done in the minor operating room at no additional cost to the patient. All the equipment needed will be provided via funding.
* Using the WOMAC scores and visual analogue scale, pain and functional outcomes before and after the procedures will be studied to assess if PRP injection is superior to steroid injection.
* Selected patients will be informed of the study and given an informed consent to fill out once they meet inclusion criteria. Persons consenting will be Orthopaedic residents knowledgeable of the study but will not be a part of the care.
* One person who is not a part of analyzing the data will be in charge of assigning the unique identifying number to each tested knee prior to the start of the study.
* WOMAC questionnaire will be administered at the outpatient clinic visits prior to injection, at two weeks, three months, six months, and a year post-injection.
* Information will be stored on a password-encrypted external storage device that can only be accessed by the investigator or supervisor. Data will be analyzed using Statistical Package for the Social Sciences (SPSS)
Research-related justification for sample size:
The sample size was calculated to be one hundred and sixty patients (160). Calculations for the sample size were done using the formula to calculate the sample size for a two-sample test of means; independent samples T-test. Where:
The type I error rate (5%) The type II error rate (20%)
= The effect size (set at 0.5 for a medium effect size).
Yields a sample size of 64 participants for each group. It is recommended to account for a loss to follow-up of at least 20%, bringing the sample size required for each group to 80, for a total sample size of 160.
Additionally, when considering sample size estimates a larger sample size is always considered better. To estimate a linear regression model to control for other factors such as age and sex, Green (1991) recommends that the sample size should be at least 50 +8\*(number of predictors). When seeking to test individual predictors, Green's rule of thumb for a medium effect size is that the sample size be at least 104 + predictors.
Using the estimate of 160, the study should be adequately powered for analysis testing the hypothesis of WOMAC pain scores being different in the group receiving PRP injections compared to the group receiving corticosteroid injection, while controlling for 2 - 3 other characteristics.
Patients will be randomized with the help of an online randomization tool (National Cancer Institute Clinical Trial randomization tool) being placed in one of two arms, corticosteroid vs PRP injection.
Patients will be recruited by the investigator and recruited for the study over 6 months with a further follow-up of up to one year post-injection. The persons assessing the patients at each visit plus the physiotherapist will not be aware of the intervention given.
Patients will be given a single injection of either PRP or corticosteroids (triamcinolone).
All injections will be given by persons post part 1 in the Doctorate of Medicine Orthopaedic program or higher except for the investigators. All patients will have 30 ml of blood taken in an area separate from the location of the centrifuge machine to prepare the PRP.
Patients and administrators will be blinded to the injection by wrapping each syringe before injection. All patients will be injected 20 minutes after the blood has been drawn. The tubes will be sorted by an individual who will know about the desired randomization. Patients will be blinded to the injection as the syringe will be wrapped to hide its content, this will also blind the person administering the injection; who is separate from the person preparing.
The steroid injections are commercially packaged as 40mg/ml. 80 mg of triamcinolone will be used for patients receiving steroids. Preparation of the PRP will be done by the PRP method.
PRP method:
1. Obtain 30mls Whole Blood by venepuncture in acid citrate dextrose (ACD) tubes
2. Do not chill the blood at any time before or during platelet separation.
3. Centrifuge the blood using a 'soft' spin.
4. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).
5. Centrifuge tube at a higher speed (a hard spin ) to obtain a platelet concentrate.
6. The lower 1/3rd is PRP and upper 2/3rd is platelet- poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.
7. Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube.
The procedure will be done in the minor operating theatre. Patients will be adequately cleaned with betadine or hibitane in alcohol before venepuncture. Blood will then be brought to a separate sterile room for preparation. Injections will be given under aseptic conditions. The area will be cleaned thoroughly with Povidone-Iodine or Hibitane in 70% Alcohol, depending on the allergy profiles of the patients. With the knee flexed to ninety degrees injection will be given with a 22 gauge needle through the lateral parapatellar space. Dressings will then be applied and patients will be observed for five minutes after the injections, post-procedural analgesics will be given for two days.
Patients will be assessed before injection, at 2 weeks, 3 months, 6 months, and a year post-injection using the WOMAC (Western Ontario and McMaster Osteoarthritis index) and Visual Analogue Score (VAS), by a trained physician who will be blinded to the interventions. There will also be a standardized rehab program for osteoarthritis of the knee developed by the physiotherapy department. This program will be administered for a duration of 6 months to all patients by volunteer registered Physiotherapists in the department.
The proposed start time of the study is July 2023 with the recruitment of patients over 6 months, followed by a one-year follow-up for each patient.
This study is a randomized controlled trial with a sample size of one hundred and sixty patients (160). Patients would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies) with knee osteoarthritis.
The recruitment period will run from July 31, 2023 to January 31, 2024 and a subsequent year of follow-up for each patient.
Selected patients will be informed of the study and given informed consent to fill out once they meet the inclusion criteria. Information will be stored on a password-encrypted external storage device that can only be accessed by the investigator or supervisor. Data will be analyzed using Statistical Package for the Social Sciences (SPSS).
The study will be conducted according to the good clinical practice guidelines of the World Medical Association (WMA) declaration of Helsinki which addresses research on human subjects and will conform to local laws and ethical requirements of the Ministry of Health.
The study will provide information on the effectiveness of two non-operative management of osteoarthritis of the knee; in the form of Platelet-rich plasma and corticosteroid injection. Results from the study can be used as a reference point for future treatment in patients with knee osteoarthritis.
Hypothesis:
PRP is superior to corticosteroid intra-articular injection over one year for knee pain and functional outcome in patients with osteoarthritis of the knee
Design This study is a randomized controlled double-blinded trial. Patients with knee osteoarthritis would be recruited via new referrals and follow-up appointments in the Orthopaedic clinic at the UHWI (University Hospital of the West Indies).
The intervention will be done in the minor operating room at no additional cost to the patient. All the equipment needed will be provided via funding.
* Using the WOMAC scores and visual analogue scale, pain and functional outcomes before and after the procedures will be studied to assess if PRP injection is superior to steroid injection.
* Selected patients will be informed of the study and given an informed consent to fill out once they meet inclusion criteria. Persons consenting will be Orthopaedic residents knowledgeable of the study but will not be a part of the care.
* One person who is not a part of analyzing the data will be in charge of assigning the unique identifying number to each tested knee prior to the start of the study.
* WOMAC questionnaire will be administered at the outpatient clinic visits prior to injection, at two weeks, three months, six months, and a year post-injection.
* Information will be stored on a password-encrypted external storage device that can only be accessed by the investigator or supervisor. Data will be analyzed using Statistical Package for the Social Sciences (SPSS)
Research-related justification for sample size:
The sample size was calculated to be one hundred and sixty patients (160). Calculations for the sample size were done using the formula to calculate the sample size for a two-sample test of means; independent samples T-test. Where:
The type I error rate (5%) The type II error rate (20%)
= The effect size (set at 0.5 for a medium effect size).
Yields a sample size of 64 participants for each group. It is recommended to account for a loss to follow-up of at least 20%, bringing the sample size required for each group to 80, for a total sample size of 160.
Additionally, when considering sample size estimates a larger sample size is always considered better. To estimate a linear regression model to control for other factors such as age and sex, Green (1991) recommends that the sample size should be at least 50 +8\*(number of predictors). When seeking to test individual predictors, Green's rule of thumb for a medium effect size is that the sample size be at least 104 + predictors.
Using the estimate of 160, the study should be adequately powered for analysis testing the hypothesis of WOMAC pain scores being different in the group receiving PRP injections compared to the group receiving corticosteroid injection, while controlling for 2 - 3 other characteristics.
Patients will be randomized with the help of an online randomization tool (National Cancer Institute Clinical Trial randomization tool) being placed in one of two arms, corticosteroid vs PRP injection.
Patients will be recruited by the investigator and recruited for the study over 6 months with a further follow-up of up to one year post-injection. The persons assessing the patients at each visit plus the physiotherapist will not be aware of the intervention given.
Patients will be given a single injection of either PRP or corticosteroids (triamcinolone).
All injections will be given by persons post part 1 in the Doctorate of Medicine Orthopaedic program or higher except for the investigators. All patients will have 30 ml of blood taken in an area separate from the location of the centrifuge machine to prepare the PRP.
Patients and administrators will be blinded to the injection by wrapping each syringe before injection. All patients will be injected 20 minutes after the blood has been drawn. The tubes will be sorted by an individual who will know about the desired randomization. Patients will be blinded to the injection as the syringe will be wrapped to hide its content, this will also blind the person administering the injection; who is separate from the person preparing.
The steroid injections are commercially packaged as 40mg/ml. 80 mg of triamcinolone will be used for patients receiving steroids. Preparation of the PRP will be done by the PRP method.
PRP method:
1. Obtain 30mls Whole Blood by venepuncture in acid citrate dextrose (ACD) tubes
2. Do not chill the blood at any time before or during platelet separation.
3. Centrifuge the blood using a 'soft' spin.
4. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).
5. Centrifuge tube at a higher speed (a hard spin ) to obtain a platelet concentrate.
6. The lower 1/3rd is PRP and upper 2/3rd is platelet- poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.
7. Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube.
The procedure will be done in the minor operating theatre. Patients will be adequately cleaned with betadine or hibitane in alcohol before venepuncture. Blood will then be brought to a separate sterile room for preparation. Injections will be given under aseptic conditions. The area will be cleaned thoroughly with Povidone-Iodine or Hibitane in 70% Alcohol, depending on the allergy profiles of the patients. With the knee flexed to ninety degrees injection will be given with a 22 gauge needle through the lateral parapatellar space. Dressings will then be applied and patients will be observed for five minutes after the injections, post-procedural analgesics will be given for two days.
Patients will be assessed before injection, at 2 weeks, 3 months, 6 months, and a year post-injection using the WOMAC (Western Ontario and McMaster Osteoarthritis index) and Visual Analogue Score (VAS), by a trained physician who will be blinded to the interventions. There will also be a standardized rehab program for osteoarthritis of the knee developed by the physiotherapy department. This program will be administered for a duration of 6 months to all patients by volunteer registered Physiotherapists in the department.
The proposed start time of the study is July 2023 with the recruitment of patients over 6 months, followed by a one-year follow-up for each patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Knee Osteoarthritis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Caregivers
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Corticosteroid Injection
This arm will receive a corticosteroid (Triamcinalone) injection.
Group Type
ACTIVE_COMPARATOR
Triamcinolone
Intervention Type
DRUG
Standard treatment for osteoarthritis knee pain
Platelet Rich Plasma Injection (PRP)
This arm will receive a PRP injection.
Group Type
ACTIVE_COMPARATOR
Platelet Rich Plasma
Intervention Type
OTHER
Alternative treatment for osteoarthritis knee pain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triamcinolone
Standard treatment for osteoarthritis knee pain
Intervention Type
DRUG
Platelet Rich Plasma
Alternative treatment for osteoarthritis knee pain
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Corticosteroid
PRP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Kellgren and Lawrence grades 2-3 Age 50 years and older
Exclusion Criteria
1. Patients with secondary OA:
2. History of Fractures around the knee joint i. patella ii. tibia plateau iii. intra articular distal femur
3. Bleeding diathesis
4. History of septic arthritis
5. Patients on oral steroid medications
6. Patients who received intraarticular steroid injection \< 6 months before enrollment
7. Sickle Cell Disease
8. Rheumatoid arthritis
9. Patients with a diagnosis of knee OA with little or no pain
10. Patient with a diagnosis of knee OA being successfully managed with oral medications and physiotherapy
11. Knee pain not attributed to a diagnosis of OA
12. All patients who refuse to participate
2. History of Fractures around the knee joint i. patella ii. tibia plateau iii. intra articular distal femur
3. Bleeding diathesis
4. History of septic arthritis
5. Patients on oral steroid medications
6. Patients who received intraarticular steroid injection \< 6 months before enrollment
7. Sickle Cell Disease
8. Rheumatoid arthritis
9. Patients with a diagnosis of knee OA with little or no pain
10. Patient with a diagnosis of knee OA being successfully managed with oral medications and physiotherapy
11. Knee pain not attributed to a diagnosis of OA
12. All patients who refuse to participate
Minimum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of The West Indies
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wayne Palmer
Role: PRINCIPAL_INVESTIGATOR
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of the West Indies
Kingston, , Jamaica
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Jamaica
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Forogh B, Mianehsaz E, Shoaee S, Ahadi T, Raissi GR, Sajadi S. Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: a double-blind randomized clinical trial. J Sports Med Phys Fitness. 2016 Jul-Aug;56(7-8):901-8. Epub 2015 Jul 14.
Reference Type
BACKGROUND
Hirsch G, Kitas G, Klocke R. Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief--a systematic review. Semin Arthritis Rheum. 2013 Apr;42(5):451-73. doi: 10.1016/j.semarthrit.2012.08.005. Epub 2013 Jan 29.
Reference Type
BACKGROUND
Migliorini F, Driessen A, Quack V, Sippel N, Cooper B, Mansy YE, Tingart M, Eschweiler J. Comparison between intra-articular infiltrations of placebo, steroids, hyaluronic and PRP for knee osteoarthritis: a Bayesian network meta-analysis. Arch Orthop Trauma Surg. 2021 Sep;141(9):1473-1490. doi: 10.1007/s00402-020-03551-y. Epub 2020 Jul 28.
Reference Type
BACKGROUND
Richards MM, Maxwell JS, Weng L, Angelos MG, Golzarian J. Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicine. Phys Sportsmed. 2016;44(2):101-8. doi: 10.1080/00913847.2016.1168272. Epub 2016 Apr 4.
Reference Type
BACKGROUND
Rayegani SM, Raeissadat SA, Taheri MS, Babaee M, Bahrami MH, Eliaspour D, Ghorbani E. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. Orthop Rev (Pavia). 2014 Sep 18;6(3):5405. doi: 10.4081/or.2014.5405. eCollection 2014 Aug 8.
Reference Type
BACKGROUND
Gormeli G, Gormeli CA, Ataoglu B, Colak C, Aslanturk O, Ertem K. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc. 2017 Mar;25(3):958-965. doi: 10.1007/s00167-015-3705-6. Epub 2015 Aug 2.
Reference Type
BACKGROUND
Liow Y, Wang W, Loh VW. Outpatient management of knee osteoarthritis. Singapore Med J. 2017 Oct;58(10):580-584. doi: 10.11622/smedj.2017097.
Reference Type
BACKGROUND
Paik J, Duggan ST, Keam SJ. Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee. Drugs. 2019 Mar;79(4):455-462. doi: 10.1007/s40265-019-01083-3.
Reference Type
BACKGROUND
Filardo G, Previtali D, Napoli F, Candrian C, Zaffagnini S, Grassi A. PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Cartilage. 2021 Dec;13(1_suppl):364S-375S. doi: 10.1177/1947603520931170. Epub 2020 Jun 19.
Reference Type
BACKGROUND
Green SB. How Many Subjects Does It Take To Do A Regression Analysis. Multivariate Behav Res. 1991 Jul 1;26(3):499-510. doi: 10.1207/s15327906mbr2603_7.
Reference Type
BACKGROUND
Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CREC-MN.023, 2022/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ketorolac Versus Triamcinolone Knee Injections for Osteoarthritis
NCT02295189
COMPLETED
NA
Effect of Steroid Injections in a Knee With Osteoarthritis
NCT01230424
COMPLETED
PHASE4
Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation
NCT01335321
COMPLETED
PHASE4
Platelet-rich Plasma Intra-articular Knee Injections for Knee Osteoarthritis
NCT01381081
COMPLETED
PHASE3
Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain
NCT06793982
RECRUITING
PHASE4
Treatment of Osteoarthrosis of the Knee With Platelet Rich Plasma, Comparative Study With Hyaluronic Acid
NCT03477630
COMPLETED
PHASE3
Is Botox Effective in Relieving Pain From Knee Osteoarthritis?
NCT00279903
COMPLETED
PHASE1
Efficacy of Intra-articular NSAID Versus Corticosteroid in the Treatment of Shoulder and Knee Conditions: A Randomized, Double-Blind, Prospective Study
NCT03616340
UNKNOWN
PHASE3
Intraarticular Injections of Platelet-rich Plasma in Pain's Treatment of the Osteoarthritic Knee
NCT02448407
COMPLETED
PHASE3
Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial
NCT02995083
WITHDRAWN
EARLY_PHASE1
Knee Injection RCT
NCT03694821
TERMINATED
PHASE4
Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes.
NCT02176304
COMPLETED
PHASE4
The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee
NCT01926327
COMPLETED
PHASE3
Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis
NCT02576249
COMPLETED
PHASE4
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis
NCT05906433
RECRUITING
PHASE1
Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
NCT06082531
RECRUITING
NA
Efficacy and Safety of Intra-articular Injections of Frozen Platelet-Rich Plasma in Patients With Knee Osteoarthritis
NCT07329361
RECRUITING
NA
Triamcinolone Ketorolac (TriKe) Knee Trial
NCT05336968
RECRUITING
PHASE4
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
NCT05806021
RECRUITING
PHASE4
A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee
NCT02024529
COMPLETED
PHASE3
Knee Osteoarthritis: Platelet Rich Plasma or Hyaluronic Acid
NCT03801564
UNKNOWN
NA
Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis
NCT03491761
RECRUITING
PHASE2
Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis
NCT02039531
COMPLETED
PHASE3
Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections
NCT02612272
UNKNOWN
PHASE4
Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis
NCT03047096
UNKNOWN
PHASE1